QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Cumberland Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CPIX)

$1.77
+0.10 (+5.99%)
(As of 11/28/2023 ET)
Compare
Today's Range
$1.65
$1.77
50-Day Range
$1.60
$2.30
52-Week Range
$1.43
$2.91
Volume
4,824 shs
Average Volume
20,459 shs
Market Capitalization
$25.24 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CPIX stock logo

About Cumberland Pharmaceuticals Stock (NASDAQ:CPIX)

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

CPIX Stock Price History

CPIX Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Cumberland man arrested in handgun assault
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Cumberland's Kibiwott takes 46th at NAIA nationals
Bobcat spotted in Cumberland
See More Headlines
Receive CPIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cumberland Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/05/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:CPIX
CUSIP
23077010
Employees
85
Year Founded
1999

Profitability

Net Income
$-5,570,000.00
Pretax Margin
-6.15%

Debt

Sales & Book Value

Annual Sales
$42.01 million
Cash Flow
$0.47 per share
Book Value
$2.45 per share

Miscellaneous

Free Float
8,259,000
Market Cap
$24.38 million
Optionable
Optionable
Beta
0.22

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. A. J. Kazimi MBA (Age 65)
    Founder, Chairman, President & CEO
    Comp: $897.5k
  • Mr. John Michael Hamm (Age 67)
    Chief Financial Officer
    Comp: $231.38k
  • Mr. James Lowrance Herman (Age 68)
    Executive VP of National Accounts & Chief Compliance Officer
    Comp: $352.65k
  • Ms. Jean W. Marstiller (Age 73)
    Senior VP of Administrative Services & Corporate Secretary
    Comp: $282.17k
  • Mr. Chris T. Bitterman (Age 58)
    Vice President of Sales & Marketing
  • Mr. Adam S. Mostafa (Age 43)
    Managing Director
  • Mr. Todd M. Anthony (Age 62)
    Vice President of Organizational Development
  • Ms. Erin Smith Gull
    Senior Corporate Relations Associate














CPIX Stock Analysis - Frequently Asked Questions

How have CPIX shares performed in 2023?

Cumberland Pharmaceuticals' stock was trading at $2.25 at the beginning of the year. Since then, CPIX stock has decreased by 21.3% and is now trading at $1.77.
View the best growth stocks for 2023 here
.

Are investors shorting Cumberland Pharmaceuticals?

Cumberland Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 18,600 shares, a drop of 25.6% from the October 31st total of 25,000 shares. Based on an average daily trading volume, of 18,100 shares, the short-interest ratio is presently 1.0 days. Currently, 0.2% of the company's stock are short sold.
View Cumberland Pharmaceuticals' Short Interest
.

When is Cumberland Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CPIX earnings forecast
.

How were Cumberland Pharmaceuticals' earnings last quarter?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) announced its quarterly earnings results on Tuesday, November, 7th. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $10.09 million for the quarter. Cumberland Pharmaceuticals had a positive trailing twelve-month return on equity of 8.68% and a negative net margin of 6.17%.

What is A. J. Kazimi's approval rating as Cumberland Pharmaceuticals' CEO?

9 employees have rated Cumberland Pharmaceuticals Chief Executive Officer A. J. Kazimi on Glassdoor.com. A. J. Kazimi has an approval rating of 9% among the company's employees. This puts A. J. Kazimi in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Cumberland Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cumberland Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), CymaBay Therapeutics (CBAY), Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Akero Therapeutics (AKRO), Cerecor (CERC), Xeris Biopharma (XERS).

Who are Cumberland Pharmaceuticals' major shareholders?

Cumberland Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.52%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include A J Kazimi, A J Kazimi, Caroline Young, James Jones, Joseph C Galante, Kenneth Krogulski, Martin E Cearnal, Martin E Cearnal and William Sumas.
View institutional ownership trends
.

How do I buy shares of Cumberland Pharmaceuticals?

Shares of CPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CPIX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -